Loading company…
ID 205187091 · FY 2020–2023 · 4 years
რომლის ძირითადი საქმიანობაა საცალო ვაჭრობა სამედიცინო და ორთოპედიული საქონლით სპეციალიზებულ მაღაზიებში, საბითუმო ვაჭრობა ფარმაცევტული საქონლით.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2020 | 2021 | 2022 | 2023 | CAGR |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | 542 | 60 | 663 | 217 | -26.2% |
| Net Cash used in Investing Activities | -18 | -26 | -5 | -185 | +117.1% |
| Free Cash Flow (OCF − Capex proxy) | 523 | 35 | 657 | 32 | -60.5% |
| Net Cash from Financing Activities | -242 | -6 | -329 | -342 | +12.2% |
| Net Change in Cash (before FX) | 281 | 29 | 329 | -309 | nmf |
| Effect of FX on Cash | 26 | -16 | -21 | -5 | nmf |
| Net Change in Cash (incl. FX) | 307 | 13 | 308 | -314 | nmf |
| Cash at Beginning of Year | 17 | 324 | 336 | 644 | +237.9% |
| Cash at End of Year | 324 | 336 | 644 | 329 | +0.6% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).